Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-7. (Canceled)

8. (Currently Amended) A method of inhibiting angiogenesis in pathological conditions where increased angiogenesis and coincidental vascular perfusion are clinically detrimental, comprising the steps of: producing an AT_4 receptor ligand, having a structure selected from the group consisting of NH_3^+-norleucine-tyrosine-isoleucine-histidine-COO^- (SEQ ID NO: 4), and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-$CONH_2$ (SEQ ID NO: 1); and administering the AT_4 receptor ligand.

9. (Allowed) The method of inhibiting angiogenesis according to claim 8 or claim 29, further comprising the delivery of the AT_4 receptor ligand locally.

10. (Allowed) The method of inhibiting angiogenesis according to claim 8 or claim 29, further comprising the delivery of the AT_4 receptor ligand intravascularly.

11. (Allowed) The method of inhibiting angiogenesis according to claim 8 or claim 29, further comprising the delivery of the AT_4 receptor ligand intramuscularly.

12. (Allowed) The method of inhibiting angiogenesis according to claim 8 or claim 29, further comprising the delivery of the AT_4 receptor ligand intraperitoneally.

~~13~~ 7. (Allowed) The method of inhibiting angiogenesis according to claim ~~8~~ 1 or claim ~~29~~ 2, further comprising the delivery of the AT_4 receptor ligand subcutaneously.

~~14~~ 8. (Allowed) The method of inhibiting angiogenesis according to claim ~~8~~ 1 or claim ~~29~~ 2, further comprising the delivery of the AT_4 receptor ligand orally.

~~15~~ 9. (Currently Amended) A method of inhibiting the growth and metastasis of solid tumors, comprising the steps of: producing an AT_4 receptor ligand, having a structure selected from the group consisting of: NH_3^+-norleucine-tyrosine-isoleucine-histidine-COO^- (SEQ ID NO: 4), and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-$CONH_2$ (SEQ ID NO: 1); and administering the AT_4 receptor ligand.

~~16~~ 11. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim ~~15~~ 9 or claim ~~30~~ 10, further comprising delivery of the AT_4 receptor ligand locally.

~~17~~ 12. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim ~~15~~ 9 or claim ~~30~~ 10, further comprising the delivery of the AT_4 receptor ligand intravascularly.

~~18~~ 13. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim ~~15~~ 9 or claim ~~30~~ 10, further comprising the delivery of the AT_4 receptor ligand intramuscularly.

~~19~~ 14. (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim ~~15~~ 9 or claim ~~30~~ 10, further comprising the delivery of the AT_4 receptor ligand intraperitoneally.

15
~~20.~~ (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim ~~15~~ 9 or claim ~~30~~ 10, further comprising the step of applying the AT_4 receptor ligand subcutaneously.

16
~~21.~~ (Allowed) The method of inhibiting the growth and metastasis of solid tumors according to claim ~~15~~ 9 or claim ~~30~~ 10, further comprising the step of applying the AT_4 receptor ligand orally.

17
~~22.~~ (Currently Amended) A method of inhibiting the growth and metastasis of breast cancer, comprising the steps of: producing an AT_4 receptor ligand, having a structure selected from the group consisting of: NH_3^+-norleucine-tyrosine-isoleucine-histidine-COO^- (SEQ ID NO: 4), and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-$CONH_2$ (SEQ ID NO: 1); and administering the AT_4 receptor ligand.

18
~~23.~~ (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim ~~22~~ 17 or claim ~~31~~ 18, further comprising the delivery of the AT_4 receptor ligand locally to the tumor.

19
~~24.~~ (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim ~~22~~ 17 or claim ~~31~~ 18, further comprising the delivery of the AT_4 receptor ligand intravascularly.

20
~~25.~~ (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim ~~22~~ 17 or claim ~~31~~ 18, further comprising the delivery of the AT_4 receptor ligand intramuscularly.

21
~~26.~~ (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim ~~22~~ 17 or claim ~~31~~ 18, further comprising the delivery of the AT_4 receptor ligand intraperitoneally.

23 ~~27~~. (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim ~~22~~ 17 or claim ~~31~~ 18, further comprising the delivery of the AT_4 receptor ligand subcutaneously.

24 ~~28~~. (Allowed) The method of inhibiting the growth and metastasis of breast cancer according to claim 22 or claim 31, further comprising the delivery of the AT_4 receptor ligand orally.

2 ~~29~~. (Currently Amended) A method of inhibiting angiogenesis in pathological conditions where increased angiogenesis and coincidental vascular perfusion are clinically detrimental, comprising the steps of: producing an AT_4 receptor ligand having a structure of: norleucine-tyrosine-leucine-Ψ-$(CH_2\text{-}NH_2)^{3\text{-}4}$-histidine-proline-phenylalanine-COO^- (SEQ ID NO: 3); and administering the AT_4 receptor ligand.

10 ~~30~~. (Currently Amended) A method of inhibiting the growth and metastasis of solid tumors, comprising the steps of: producing an AT_4 receptor ligand having a structure of: norleucine-tyrosine-leucine-Ψ-$(CH_2\text{-}NH_2)^{3\text{-}4}$-histidine-proline-phenylalanine-COO^- (SEQ ID NO: 3); and administering the AT_4 receptor ligand.

18 ~~31~~. (Currently Amended) A method of inhibiting the growth and metastasis of breast cancer, comprising the steps of: producing an AT_4 receptor ligand having a structure of: norleucine-tyrosine-leucine-Ψ-$(CH_2\text{-}NH_2)^{3\text{-}4}$-histidine-proline-phenylalanine-COO^- (SEQ ID NO: 3); and administering the AT_4 receptor ligand.